Drug Trial Radar · NCT06603077
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
253
Actual
Start
Sep 16, 2024
Primary completion
Feb 23, 2026
Study completion Mar 17, 2026
Sponsor
- Lead sponsor
- Avalo Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Conditions
- Hidradenitis Suppurativa
Interventions
AVTX-009 Regimen 1Drug
AVTX-009 will be administered as a subcutaneous injection every 4 weeks.
AVTX-009 Regimen 2Drug
AVTX-009 will be administered as a subcutaneous injection every 2 weeks.
PlaceboDrug
Matching placebo will be administered as a subcutaneous injection every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: At Week 16
Locations
89 sites in 13 countries. Site status is shown where the registry gives one.
Clinical Site 1022
Scottsdale, Arizona
Clinical Site 1037
Scottsdale, Arizona
Clinical Site 1026
Tucson, Arizona
Clinical Site 1032
Northridge, California
Clinical Site 1019
Pomona, California
Clinical Site 1009
Sacramento, California
Clinical Site 1034
Santa Monica, California
Clinical Site 1011
Washington D.C., District of Columbia
Clinical Site 1029
Boca Raton, Florida
Clinical Site 1002
Coral Gables, Florida
Clinical Site 1015
Maitland, Florida
Clinical Site 1027
North Miami Beach, Florida
Clinical Site 1013
Tampa, Florida
Clinical Site 1008
Savannah, Georgia
Clinical Site 1014
Chicago, Illinois
Clinical Site 1028
West Lafayette, Indiana
Clinical Site 1031
Bowling Green, Kentucky
Clinical Site 1024
Murray, Kentucky
Clinical Site 1042
Boston, Massachusetts
Clinical Site 1001
Boston, Massachusetts
Clinical Site 1030
Detroit, Michigan
Clinical Site 1007
Fort Gratiot, Michigan
Clinical Site 1041
Oakland, Michigan
Clinical Site 1003
Portsmouth, New Hampshire
Clinical Site 1036
Brooklyn, New York
Clinical Site 1016
New York, New York
Clinical Site 1023
The Bronx, New York
Clinical Site 1020
Cincinnati, Ohio
Clinical Site 1010
Cleveland, Ohio
Clinical Site 1017
Dublin, Ohio
Clinical Site 1004
Philadelphia, Pennsylvania
Clinical Site 1035
Pittsburgh, Pennsylvania
Clinical Site 1018
Johnston, Rhode Island
Clinical Site 1025
Providence, Rhode Island
Clinical Site 1005
Greenville, South Carolina
Clinical Site 1012
Arlington, Texas
Clinical Site 1203
Darlinghurst, New South Wales, Australia
Clinical Site 1201
Westmead, New South Wales, Australia
Clinical Site 1204
Woolloongabba, Queensland, Australia
Clinical Site 1202
Carlton, Victoria, Australia
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.